newsfilter
← Latest News
GlobeNewswire·

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201